Novel therapeutic options with improved efficacy and safety profiles are needed for the prophylaxis of migraine. In recent years, the inhibition of calcitonin gene-related peptide (CGRP) signaling has attracted growing interest in the pharmacological research on migraine. Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.
Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety / Lattanzi, Simona; Brigo, Francesco; Trinka, Eugen; Vernieri, Fabrizio; Corradetti, Tommaso; Dobran, Mauro; Silvestrini, Mauro. - In: DRUGS. - ISSN 0012-6667. - STAMPA. - (2019). [10.1007/s40265-019-01069-1]
Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety
Lattanzi, Simona
;Corradetti, TommasoInvestigation
;Dobran, MauroInvestigation
;Silvestrini, MauroSupervision
2019-01-01
Abstract
Novel therapeutic options with improved efficacy and safety profiles are needed for the prophylaxis of migraine. In recent years, the inhibition of calcitonin gene-related peptide (CGRP) signaling has attracted growing interest in the pharmacological research on migraine. Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
